The promyelocytic leukemia zinc finger-microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms

Cancer Research
Federica FelicettiAlessandra Carè

Abstract

The incidence of cutaneous melanoma is steadily increasing. Although several molecular abnormalities have been associated with melanoma progression, the mechanisms underlying the differential gene expression are still largely unknown and targeted therapies are not yet available. Noncoding small RNAs, termed microRNAs (miR), have been recently reported to play important roles in major cellular processes, including those involved in cancer development and progression. We have identified the promyelocytic leukemia zinc finger (PLZF) transcription factor as a repressor of miR-221 and miR-222 by direct binding to their putative regulatory region. Specifically, PLZF silencing in melanomas unblocks miR-221 and miR-222, which in turn controls the progression of the neoplasia through down-modulation of p27Kip1/CDKN1B and c-KIT receptor, leading to enhanced proliferation and differentiation blockade of the melanoma cells, respectively. In vitro and in vivo functional studies, including the use of antisense "antagomir" oligonucleotides, confirmed the key role of miR-221/-222 in regulating the progression of human melanoma; this suggests that targeted therapies suppressing miR-221/-222 may prove beneficial in advanced melanoma.

Citations

Nov 26, 2008·World Journal of Surgery·Min LiChangyi Chen
Oct 12, 2012·Amino Acids·Nadine TandlerJens Pietzsch
Feb 5, 2010·Cancer Metastasis Reviews·Liqin Du, Alexander Pertsemlidis
Jun 12, 2012·Cancer Metastasis Reviews·Aaron K MobleyMenashe Bar-Eli
Feb 22, 2012·Journal of Mammary Gland Biology and Neoplasia·Erin N HoweJennifer K Richer
Feb 1, 2012·Cancer Letters·Edward S GreenbergDave S B Hoon
Aug 22, 2013·Cancer Letters·Chonglin LuoStefan B Eichmüller
Feb 2, 2013·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Seyed Mehdi JafarnejadGang Li
May 5, 2012·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Yoon K JeonSeong H Park
Aug 20, 2008·Nature Immunology·Laurent Gapin
Jun 13, 2009·Proceedings of the National Academy of Sciences of the United States of America·Ryo UedaHideho Okada
Jun 14, 2012·Carcinogenesis·Miguel F SeguraEva Hernando
Feb 1, 2013·Journal of the National Cancer Institute·Altaf A DarMohammed Kashani-Sabet
Jun 1, 2012·The Cancer Journal·Stine B ThorsenSakari Kauppinen
Aug 13, 2009·Pigment Cell & Melanoma Research·Daniel W Müller, Anja K Bosserhoff
Jun 19, 2010·Pigment Cell & Melanoma Research·Daniel W Mueller, Anja-Katrin Bosserhoff
Oct 5, 2010·Pigment Cell & Melanoma Research·Amy E RoseIman Osman
Mar 26, 2011·Pigment Cell & Melanoma Research·Glen M BoyleNicholas K Hayward
Jun 30, 2011·Pigment Cell & Melanoma Research·Gianfranco MattiaAlessandra Carè
Jan 18, 2012·Pigment Cell & Melanoma Research·Ken Dutton-Regester, Nicholas K Hayward
Mar 11, 2009·Molecular and Cellular Biology·Rafael CuestaFátima Gebauer
May 26, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Audrey VincentMichael Goggins
Apr 29, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Alvaro J AlencarIzidore S Lossos
May 31, 2011·Molecular Cancer Therapeutics·Dipankar PramanikAnirban Maitra
Jun 15, 2010·Journal of Translational Medicine·Luca SigalottiMichele Maio
Apr 10, 2013·Experimental Hematology & Oncology·Hamilton L Gimenes-TeixeiraEduardo M Rego
Nov 4, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Marilena V Iorio, Carlo M Croce
Apr 28, 2010·The AAPS Journal·Mengfeng LiShi-Yuan Cheng
Sep 26, 2009·PLoS Computational Biology·William RitchieJohn E J Rasko
Mar 20, 2010·PloS One·Mitchell S StarkNicholas K Hayward

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.